NCT00140062已完成4 期
A Randomized Post-Marketing Efficacy And Safety Study Of Xalatan Compared With "Usual Care" Over 36 Months In Patients With Primary Open-Angle Glaucoma, Exfoliative Glaucoma Or Ocular Hypertension
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 329
- 试验地点
- 27
- 主要终点
- Time to treatment failure (change or addition of ocular hypertensive medical treatment, ocular surgery or laser trabeculoplasty) of latanoprost monotherapy or usual care over 36 months.
研究概览
简要总结
The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Unilateral or bilateral open-angle glaucoma, exfoliative glaucoma, pigmentary glaucoma or ocular hypertension
- •IOP of > 21 mm Hg on current treatment
排除标准
- •Any previous or current treatment with latanoprost or other prostaglandin analogues
结局指标
主要结局
Time to treatment failure (change or addition of ocular hypertensive medical treatment, ocular surgery or laser trabeculoplasty) of latanoprost monotherapy or usual care over 36 months.
次要结局
- Safety and the health care utilization in the two treatment groups over 36 months.
研究者
研究点 (27)
Loading locations...
相似试验
已完成
4 期
A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle GlaucomaGlaucoma, Open-AngleOcular HypertensionNCT00647101Pfizer's Upjohn has merged with Mylan to form Viatris Inc.600
已完成
不适用
Non Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®Glaucoma,Open-AngleOcular HypertensionNCT00486252Pfizer's Upjohn has merged with Mylan to form Viatris Inc.996
已完成
1 期
Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery VolunteersOcular InflammationNCT01190878Sun Pharmaceutical Industries Limited169
已完成
3 期
Comparison Study of ISV-303 to DuraSite Vehicle in Cataract Surgery SubjectsOcular InflammationNCT01576952Sun Pharmaceutical Industries Limited268
撤回
3 期
Safety And Efficacy Of Xalatan Delivered Using Either A Conventional Dropper Bottle or A Delivery DeviceGlaucoma, Open-AngleOcular HypertensionNCT00283764Pfizer's Upjohn has merged with Mylan to form Viatris Inc.